Molecular Mechanisms of PARP Inhibitors in BRCA-related Ovarian Cancer
ثبت نشده
چکیده
Abbreviations: PARP: Poly(Adp-Ribose) Polymerase; SSBS: Single Strand Breaks; DSBS: Double Strand Breaks; BER: Base Excision Repair; NER: Nucleic Acid Excision Repair; MMR: Mismatch Repair; HR: Homologous Recombination; NHEJ: Non-Homologous End Joining; DNA-PKCS: DNA-Dependent Protein Kinase; ORR: Objective Response Rate; PFS: Progression-Free Survival; PLD: Pegylated Liposomal Doxorubicin; OS: Overall Survival
منابع مشابه
“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been investigated in ovarian and breast cancer, showing promising efficacy in BRCA-mutated patients. Recentl...
متن کاملPARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways. The proteins encoded by breast-related cancer antigen (BRCA) and poly(adenosine diphosphate-ribose) polymerases (PARP) are involved in HR and BER, respectively. Tumors with HR deficiency, including those in BRCA mutation carriers, are sensitive to BER blockade via PARP inhibitors. These repres...
متن کاملPARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
The treatment strategy of poly(ADP-ribose) polymerase (PARP) inhibition capitalizes on the inherent defect in homologous recombination that occurs in BRCA-deficient tumors by inhibiting the alternative DNA repair pathway involving base excision repair. Although PARP inhibitors were initially considered a potential treatment specifically for tumors with germline BRCA mutations, evidence of frequ...
متن کاملNiraparib in ovarian cancer: results to date and clinical potential
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in...
متن کاملThe status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown promising clinical activity in epithelial ovarian cancer. Following the observation in vitro that PARP inhibition is synthetically lethal in tumors with BRCA mutations, PARP inhibition has become the first genotype-directed therapy for BRCA1- and BRCA2-associated ovarian cancer. However, it is becoming clear that PARP in...
متن کامل